New combo therapy targets tough cancers in early trial
Disease control
Recruiting now
This early-phase study tests a new drug called KGX101, given alone or with envafolimab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body handles the drugs. About 57 pa…
Phase: PHASE1 • Sponsor: Kangabio AUSTRALIA LTD PTY • Aim: Disease control
Last updated May 26, 2026 11:59 UTC